Evidence · Trials · continued

Primary endpoint hierarchies and why order matters — one year on posts 61–62

Evidence › Trials surrogate endpoints discontinuation & dropout estimand randomised trial Solved

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

baseline_peakTL227 Jul 2026#61

Collapsed as off-topic by two members at trust level 3 or above

Post #60 is the version of this I will quote in future. One addition.

Primary endpoint hierarchies is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.

b.nwosuTL227 Jul 2026#62

Helpful, and short, which on this subject is harder than long.

22 likes 11h

Promoted into the documentation commons. The content of this topic is maintained at Retatrutide phase 2 (type 2 diabetes) — trial digest, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

Topic	Participants	Replies	Views	Activity
Revisiting: Primary endpoint hierarchies and why order matters Evidence › Trials estimand surrogate endpoints discontinuation & dropout intention to treat Posting this under the heading it deserves: Revisiting: Primary endpoint hierarchies and why order matters Everything below is what sits behind that. I was wrong about Primary endpoint hierarchies in a thread…	+21	25	46k	3mo
Reading a supplementary appendix and finding the interesting part Evidence › Trials open label discontinuation & dropout intention to treat estimand Reading a supplementary appendix and finding the interesting part — setting out what I have, and where I think it stops being reliable. Collecting what is known about reading a supplementary appendix in one…	+87	92	1.1k	17mo
Open-label extensions: what survives and what does not Evidence › Trials discontinuation & dropout randomised trial estimand Closed Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. I have spent a fortnight trying to pin open-label extensions down…		4	22k	3mo
Second pass at: Trial registration and comparing the protocol with the paper Evidence › Trials estimand discontinuation & dropout randomised trial open label Posting this under the heading it deserves: Second pass at: Trial registration and comparing the protocol with the paper Everything below is what sits behind that. Two things I would like separated before…	+30	34	33k	13mo
Adjudicated events and why the definition matters Evidence › Trials estimand intention to treat discontinuation & dropout surrogate endpoints Under review On the subject in the title: Adjudicated events and why the definition matters Working notes rather than a conclusion. A follow-up question about adjudicated events that I did not know to ask the first time.…		2	4.5k	2mo

Related topics — sharing the tags surrogate endpoints, discontinuation & dropout, estimand

Topic	Participants	Replies	Views	Activity
Journal club: LEADER as the historical anchor Evidence › Journal club estimand number needed to treat journal club effect size Pinned Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of LEADER is wrong? I ask because I have…	+103	110	8.1k	2h
Why retatrutide discussion here is more cautious than elsewhere — one year on Compounds › Retatrutide TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Two things I would like separated before anyone answers on…	+92	97	3.6k	20h
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial cagrilintide On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. Trying to work out what would count as evidence on Amylin analogue…	+27	31	671	12mo
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Compounds › Cagrilintide & amylin analogues effect size cagrilintide cagrisema amylin analogues Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Nausea profile of amylin analogues — I have the…	+48	53	31k	13mo
Reading SURMOUNT-1 without the press release — one year on Compounds › Tirzepatide effect size SURPASS programme randomised trial Solved Closed Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1…	+45	50	7.6k	5mo